@article{oai:repo.qst.go.jp:00048793,
 author = {Hayashi, Kazuhiko and Koto, Masashi and Ikawa, Hiroaki and Ogawa, Kazuhiko and Kamada, Tadashi and 林 和彦 and 小藤 昌志 and 伊川 裕明 and 小川 和彦 and 鎌田 正},
 issue = {16},
 journal = {Oncotarget},
 month = {Feb},
 note = {Purpose: To evaluate the efficacy and safety of carbon-ion radiotherapy (CIRT) for patients with lacrimal gland carcionmas (LGCs) with extraorbital extension 
Results:  The median follow-up period was 53.7  months. The 5-year local control and overall survival rates were 62% and 65%, respectively. Regarding late toxicities, 12 patients (36.4%) developed Grade 4 optic nerve disorders, including visual losses of the disweased side (N = 8;66.7%), and 1 patient (3.0%) developed a Grade 3 optic nerve disorder. Three patients (9.0%) developed Grade 3 cataracts, 3 (9.0%) developed glaucoma, and 1 (3.0%) developed retinopathy. Two patients (6.1%) had Grade 4 central nervous system necrosis. No Grade 5 late toxicities were observed. The 5-year preservation rate of the ipsilateral eyeball was 86%.
Conclusion:  Definitive CIRT is effective for LGCs with extraorbital extension with acceptable toxicity.
Methods:  Thirty-three patients treated with CIRT at our institution were analyzed. Sixteen patients (48.5%) had adenoid cystic carcinoma, 8 (24.2%) had  adnocarcinoma not otherwise specified, and 9 (27.3%) had other types of the disease.  Thirty patients (90.9%) had T4c tumors. the prescribed doses were 57.6 Gy (relative biological effectiveness [RBE]) (N = 18; 54.5%) and 64.0 gy(RBE) (N = 15;45.5%) in 16 fractions.},
 pages = {12932--12940},
 title = {Efficacy and safety of carbon-ion radiotherapy for lacrimal gland carcinomas with extraorbital extension: a retrospective cohort study},
 volume = {9},
 year = {2018}
}